U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Meta Expands AI Training With Employee Activity Tracking Tools 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
BASEL, Switzerland and CAMBRIDGE, Mass., May 12, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics and Samarth Kulkarni, Ph.D., President and Chief Business Officer of CRISPR Therapeutics, will present at two upcoming Investor Conferences in May.
Event: Bank of America Merrill Lynch 2017 Health Care Conference: Gene Therapy and Gene Editing Panel
Date: Wednesday, May 17th
Time: 1:40 PM PDT
Event: UBS Global Healthcare Conference
Date: Tuesday, May 23rd
Time: 1:30 PM EDT
A live webcast of the presentation at the UBS Global Healthcare Conference can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS: Jennifer Paganelli WCG on behalf of CRISPR +1 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR +1 339-970-2843 [email protected]
